ArticlePharmaceutical research2025
Hydroquinone Hydroxypropyl-β-cyclodextrin Inclusion Complex Based Topical Cream as an Effective Treatment of Melasma by Releasing Hydroquinone in a Controlled Manner.
Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveHydroquinone (HQ) is globally regarded as the gold-standard topical agent for melasma treatment. However, its clinical utility is limited by several challenges: susceptibility to oxidation induced by light, air, and metal ions, which generates harmful byproducts and triggers adverse effects (e.g., skin irritation, pruritus, and dermatitis). Moreover, excessively high concentration in the skin of hydroquinone due to the burst release of HQ may cause melanocyte cytotoxicity, while systemic penetration raises additional safety concerns. To overcome these limitations and enhance the therapeutic applicability of HQ, this study aims to develop strategies that mitigate its instability and optimize its delivery profile.
methodsIn this study, an oil-in-water cream containing hydroquinone cyclodextrin inclusion complex (HQ-HPCD) was designed with PO as the oil phase matrix to improve the treatment of melasma.
resultsAs expected, the in vitro release profile of HQ-HPCD cream exhibited near-zero-order kinetics, effectively mitigating the irritation associated with burst release-induced peak concentrations. The HQ-HPCD inclusion complex demonstrated enhanced photostability and oxidative resistance compared to free HQ. Then it was confirmed by B16F10 cells that the HQ-HPCD increased the IC
conclusionsThis study successfully developed a topical formulation that enhances the stability of hydroquinone (HQ) while achieving its sustained release in the epidermal layer, thereby improving its clinical applicability of melasma.
Indexed as
Identifiers
41034678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.